Seeking Alpha

Cowen's Phil Nadeau says that its latest physician survey suggests sales of Regeneron's (REGN...

Cowen's Phil Nadeau says that its latest physician survey suggests sales of Regeneron's (REGN 8.9%) big revenue driver, Eylea, may be slowing. Measuring the uptake of the company's treatment for a leading cause of blindness in the elderly, the number of patients on the drug grew 22% from March to May, compared to 155% growth from January to March. Based on this level of deceleration, Cowen thinks the stock may be rich at these levels.
From other sites
Comments (1)
  • boyle99
    , contributor
    Comment (1) | Send Message
     
    Plus 122% on a small base is probably less than plus 22% on a much larger base.
    Peter Boyle - long time REGN shareholder
    1 Jun 2012, 04:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs